medigraphic.com
Colegio de Medicina Interna de México.

2010, Número 4

<< Anterior Siguiente >>

Med Int Mex 2010; 26 (4)


Fundamento científico de la oxigenoterapia hiperbárica en el tratamiento del pie diabético infectado grave en medicina basada en evidencias

Luna RCL

Idioma: Español
Referencias bibliográficas: 31
Paginas: 374-382
Archivo PDF: 275.53 Kb.


RESUMEN

Cuando se habla de oxígeno hiperbárico, casi inmediatamente se vierten opiniones negativas y descalificaciones a priori, inclusive en muchos de los casos sin conocer el fundamento científico en que se apoya. Cuando una tecnología es desconocida provoca desconfianza y al no entenderla y estudiarla a profundidad, es más fácil descalificarla. Este artículo tiene como propósito dar a conocer los aspectos generales más relevantes de la medicina hiperbárica, desde sus antecedentes históricos, su fundamento científico, sus mecanismos de acción, indicaciones actuales y los estudios de medicina basada en evidencias para su indicación a pacientes con pie diabético infectado grave.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Feldmeier JJ, et al. Hyperbaric oxygen 2003, Indications and results: UHMS Hyperbaric oxygen therapy committee report. Undersea and Hyperbaric Medical Society, 2003.

  2. Boerema I, Meyne NG, Brummeljamp WK, et al. Life without blood. A study of the influence of high atmospheric pressure. J Card Surg 1960;1:133-146.

  3. Sheffield PJ. Tissue oxygen measurements. In: Davis JC, Hunt TK, ed. Problem wounds: the role of oxygen. New York: Elsevier, 1988;p:15-52.

  4. Sánchez C, Garcia L. Terapia con oxigenación hiperbárica: conceptos básicos. Gac Med Mex 2000;136(1).

  5. Michael CD, Justin F, Steinberg JS. Hyperbaric oxygen therapy as an adjunctive treatment for diabetic foot wounds: a comprehensive review with case studies. Wounds, jan. 2010

  6. Guyton AC. Transporte de oxígeno y dióxido de carbono por la sangre y líquidos corporales. En: Guyton AC. Tratado de Fisiología Médica. México: Interamericana, 1989;p:194-495.

  7. Goodman y Gilman. Las bases farmacológicas de la terapéutica. 6a. ed. México: Panamericana, 2008.

  8. Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care 2003;26(2):491-494.

  9. Lipsky BA, et al. Infectiuos Diseases Society of America. Diagnosis and Treatment of diabetic foot infections. Clin Inf Dis 2004;39(7):885-910.

  10. Reiber GE Epidemiology of foot ulcers and amputations in the diabetic foot. In: Bowker JH Pfeifer MA eds. The diabetic foot. St Louis: Mosby, 2001;p:13-32.

  11. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003;26(6):1790-1795.

  12. Piwernetz K, Home PD, Snorgaard O, Antsiferov M, et al. Monitoring the targets of the St. Vincent Declaration and the implementation of quality management in diabetes care: the DIABCARE initiative. The DIABCARE Monitoring Group of the St. Vincent Declaration Steering Committee. Diabet Med 1993;10:371-377.

  13. Lipsky B, et al. Optimización del tratamiento antimicrobiano en infecciones del pie diabético. Drugs 2007;67(2):195-214.

  14. Edwards J. Debridement of diabetic foot ulcers. Cochrane Database of Systematic Reviews 2007, Issue 2. Cochrane Library Plus 2006 (4).

  15. American Diabetes Association: clinical practice recommendations 1995. Diabetes Care 1995;18 (Suppl 1):196.

  16. Wattel FE, Mathieu DM, Fossati P, Neviere RR, Coget JM. Hyperbaric oxygen in the treatment of diabetic foot lesions: search for healing predictive factors. J Hyperbar Med 1991;6:263-267.

  17. Hopf HW, Gibson JJ, Angeles AP, et al. Hyperoxia and angiogenesis. Wound Repair Regen 2005;13(6):558-654.

  18. Brummelkamp W, Hogen D, Boerema I. Treatment of anaerobic infections clostridial myositis by drenching the atmospheric pressure. Surgery 1961;49:299-302.

  19. Morales G, et al. Fundamento y utlidad de la oxígenoterapia hiperbárica en cirugía general. Arch Cir Gen Dig 2003 jun.

  20. Rudge FW. The role of hyperbaric oxygenation in the treatment of clostridial myonecrosis. Mil Med 1993;158(2):80-83.

  21. Demello FJ, Haglin JJ, Hitchcock CR. Comparative study of experimental Clostridium perfringens infection in dogs treated with antibiotics, surgery, and hyperbaric oxygen. Surgery 1973;73(6):936-941.

  22. Kimgthon DR, Fiegel VD, et al. Oxygen as an Antibiotic. Arch Surg 1990;97-100.

  23. Thom SR. Functional Inhibition of Leukocyte 132 Integrins by hyperbaric oxygen in carbon monoxide-mediated brain injury in rats. Toxicol Appl Pharmacol 1993;123:248-256.

  24. Mileski WJ, Silkes P, et al. Inhibition of Leukocytes Adherences and Susceptibility to the Infection. J Surg Res 1993;54(4):349- 354 (abstract).

  25. Faglia E, Favales F, Aldeghi A, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevantetly ischemic diabetic foot ulcer. Diabetes Care 1996;19:1338- 1343.

  26. Cianci P, Petrone G, Green B. Adjunctive hyperbaric oxigen in salvage of the diabetic foot. Undersea Biomedical Research 1991;18:108.

  27. Cianci P, Hunt TK. Long-term results of aggressive management of diabetic foot ulcer suggest significant cost effectiveness. Wound Repair Regen 1997;5:141-146.

  28. Allen M. The treatment of leg ulcer with hyperbaric oxygen therapy. J Tissue Viabil 1998;1:42-47.

  29. Kalani M, Jorneskog G, Naderi N, Lind F, Brismar K. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers. Long-term follow-up. J Diabetes Complications 2002;16:153- 158.

  30. Zuzuki K. A guide to hyperbaric oxygen-therapy for diabetic foot wound. Podiatry Today 2002;20(12).

  31. Chuck AW, Hailey D, Jacobs P, Perry DC. Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcers. International Journal of Technology Assessment in Health Care 2008;24(2):178-183.




2020     |     www.medigraphic.com